MARKET

TOCA

TOCA

Tocagen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5465
+0.0153
+2.88%
After Hours: 0.5695 +0.023 +4.21% 19:42 12/13 EST
OPEN
0.5303
PREV CLOSE
0.5312
HIGH
0.5699
LOW
0.5303
VOLUME
986.64K
TURNOVER
--
52 WEEK HIGH
12.00
52 WEEK LOW
0.4600
MARKET CAP
13.06M
P/E (TTM)
-0.1704
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TOCA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TOCA News

  • The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer
  • Benzinga.1d ago
  • Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncology Annual Meeting
  • PR Newswire.11/22 21:05
  • Tocagen Q3 EPS $(0.78) Misses $(0.7) Estimate, license Revenue $100K
  • Benzinga.11/12 21:35
  • Tocagen Reports Third Quarter 2019 Financial Results and Business Updates
  • PR Newswire.11/12 21:30

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About TOCA

Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells. Its lead product candidates are vocimagene amiretrorepvec (Toca 511) and flucytosine extended release (Toca FC). Toca 511 is an investigational injectable retroviral replicating vector (RRV) that encodes a prodrug activator enzyme, cytosine deaminase (CD). Toca FC is an investigational extended-release version of 5-fluorocytosine (5-FC), a prodrug that is inactive as an anti-cancer drug. As of February, 2017, Tocagen has completed enrollment of the Phase II portion with 187 patients.
More

Webull offers Tocagen Inc (TOCA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.